Clinical Trial Update: Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients [Phase 1, Phase 2]

View source ↗

Summary

Trial update describing a Phase 1/2 study of vorolanib in combination with cadonilimab for untreated advanced renal cell carcinoma, currently not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Cadonilimab
• Vorolanib (vorolanib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Kidney Cancer, RCC | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING